PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of pubhealthrepLink to Publisher's site
 
Public Health Rep. 2005 Jan-Feb; 120(1): 84–88.
PMCID: PMC1497683

Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals.

Abstract

OBJECTIVES: The purpose of this study was to determine the effect of release from prison and subsequent re-incarceration on the viral loads of HIV-infected individuals receiving highly active antiretroviral therapy (HAART). METHODS: Fifteen re-incarcerated HIV-infected prisoners on HAART were identified from a retrospective cohort of HIV-infected prison inmates released from January 1, 1997, to August 31, 1999. The re-incarcerated prisoners were matched (1:2) to 30 HIV-infected incarcerated prisoners on HAART who remained incarcerated during the re-incarcerated participants' release time period. The outcomes measured were plasma HIV RNA levels, CD4+ lymphocyte counts, percentage of re-incarcerated and incarcerated participants with plasma HIV RNA levels <400 copies/mL, and the median change in plasma HIV RNA levels of the re-incarcerated and incarcerated participants at the end of the study. RESULTS: At the beginning of the study, 8/15 re-incarcerated participants had plasma HIV RNA levels <400 copies/mL, compared with 15/30 incarcerated participants. At the end of the study, only three of those eight re-incarcerated participants had plasma HIV RNA levels <400 copies/mL, compared with 14/15 incarcerated participants (p=0.0086). The median change in plasma HIV RNA levels of the re-incarcerated participants was 1.29 log10 copies/mL (interquartile range 0.04 to 1.70), compared with -0.03 log10 copies/mL (interquartile range -0.65 to 0.09) in the incarcerated participants (p=0.0183). CONCLUSIONS: Release from prison was associated with a deleterious effect on virological and immunological outcomes. These data suggest that comprehensive discharge planning efforts are required to make certain that HIV-infected inmates receive access to quality care following incarceration.

Full Text

The Full Text of this article is available as a PDF (77K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hammett Theodore M, Harmon Mary Patricia, Rhodes William. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2002 Nov;92(11):1789–1794. [PubMed]
  • Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000 Jul 4;133(1):21–30. [PubMed]
  • Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, Christian J, Maldonado T, Duran D, Kaplan AH, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001 May 15;134(10):968–977. [PubMed]
  • Spaulding Anne, Stephenson Becky, Macalino Grace, Ruby William, Clarke Jennifer G, Flanigan Timothy P. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002 Aug 1;35(3):305–312. [PubMed]
  • Holmes-Rovner M, Kroll J, Rovner DR, Schmitt N, Rothert M, Padonu G, Talarczyk G. Patient decision support intervention: increased consistency with decision analytic models. Med Care. 1999 Mar;37(3):270–284. [PubMed]
  • Malow RM, Baker SM, Klimas N, Antoni MH, Schneiderman N, Penedo FJ, Ziskind D, Page B, McMahon R, McPherson S. Adherence to complex combination antiretroviral therapies by HIV-positive drug abusers. Psychiatr Serv. 1998 Aug;49(8):1021–1024. [PubMed]

Articles from Public Health Reports are provided here courtesy of Association of Schools of Public Health